We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
- Authors
Srivastava, G; Rana, V; Lacy, M Q; Buadi, F K; Hayman, S R; Dispenzieri, A; Gertz, M A; Dingli, D; Zeldenrust, S; Russell, S; McCurdy, A; Kapoor, P; Kyle, R; Rajkumar, S V; Kumar, S
- Abstract
The combination of lenalidomide and dexamethasone (Len-Dex) is a commonly used initial therapy for newly diagnosed multiple myeloma (MM). Although the initial response rates and toxicity are well known, long-term outcome is not well described. We studied 286 consecutive patients with newly diagnosed MM initially treated with Len-Dex. The median (range) age at diagnosis was 63 (28-92) years, 166 (58%) patients 65 years and 175 (61%) male. The median estimated duration on Len-Dex was 5.3 months with overall response (partial response) of 72%, including 26% with very good partial response or better. The median overall survival (OS) from the diagnosis was not reached (NR) and the estimated 5-year survival was 71%. The median time to first disease progression, irrespective of transplant status, was 30.2 months. Overall, 143 (50%) patients underwent stem cell transplant. The median OS was NR for patients 70 years and 5.8 years for the older patients (P=0.01). The 5-year OS estimate for patients in International Staging System stage 1, 2 and 3 were 82, 65, and 44% respectively. There were 21 new second malignancies after MM diagnosis (6.6%). The median survival exceeding 7 years reflects the efficacy of novel agents. The risk of second malignancies doesn't appear to be excessive in this population.
- Subjects
MULTIPLE myeloma; DEXAMETHASONE; B cell lymphoma; STEM cells; PATIENTS
- Publication
Leukemia (08876924), 2013, Vol 27, Issue 10, p2062
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/leu.2013.143